Abstract:Background & aims: Liver fibrosis regression but also progression may occur in patients with autoimmune hepatitis (AIH) under treatment. There is a need for non-invasive surrogate markers for fibrosis development in AIH to better guide immunosuppressive treatment. The aims of the study were to assess the impact of complete biochemical remission defined as normalisation of aminotransferases and IgG on histological activity and fibrosis development, and the value of repeat transient elastography (TE) measurement for monitoring disease progression in AIH. Methods: A total of 131 liver biopsies from 60 patients with AIH and more than 900 TE from 125 patients with AIH, 130 with primary biliary cholangitis (PBC) and 100 with primary sclerosing cholangitis (PSC), were evaluated. Time intervals between TE were at least 12 months. Patients with AIH were treated for at least six months at first TE. Results: In contrast to PBC and PSC, a decrease of liver stiffness (LS) was observed in the whole group of patients with AIH (-6.2%/year; 95% CI -12.6% to -0.2%; p = 0.04). The largest decrease of LS was observed in patients with severe fibrosis at baseline (F4: -11.7%/year; 95% CI -19% to -3.5%; p = 0.006). Complete biochemical remission was strongly linked to regression of LS ("remission": -7.5%/year vs. "no remission": +1.7%/year, p <0.001). Similarly, complete biochemical remission predicted low histological disease activity and was the only independent predictor for histological fibrosis regression (relative risk3.66; 95% CI1.54-10.2; p = 0.001). Patients with F3/F4-fibrosis, who remained in biochemical remission showed a considerable decrease of fibrosis stage (3.7 ± 0.5 to 1.8 ± 1.7; p = 0.007) on histological follow-up. Conclusions: This study demonstrates that complete biochemical remission is a reliable predictor of a good prognosis in AIH and leads to fibrosis regression that can be monitored by TE. Lay summary: Autoimmune hepatitis is an inflammatory disease of the liver, which often progresses to cirrhosis if left untreated or in the case of insufficient treatment response. Current guidelines have defined biochemical remission (normalisation of biochemical markers for liver inflammation) as a major goal in the treatment of AIH. However, data on the prognostic relevance of this definition are scarce. Herein, we demonstrate that the current definition of biochemical remission is a reliable surrogate for low disease activity on histological assessment and for a beneficial long-term disease course. In addition, we establish transient elastography, a non-invasive ultrasound-based method of measuring scarring of liver tissue, as a reliable tool to monitor disease course in AIH.

Advanced Magnetic Resonance Imaging for Detection of Liver Fibrosis and Inflammation in Autoimmune Hepatitis: A State-of-the-Art Review

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Diagnostic accuracy of an uncorrected native T1 mapping sequence for liver fibrosis and inflammation in autoimmune hepatitis: a prospective study using histopathology as reference standard

A Serum Metabolomic Analysis for Diagnosis and Biomarker Discovery of Primary Biliary Cirrhosis and Autoimmune Hepatitis.

Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis

Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future

Non-invasive diagnosis and follow-up of autoimmune hepatitis

Diffusion-weighted Imaging and Variable Flip Angle T1 Mapping: a Supplement for Image-Guided Biopsy in Follow-Up Analysis of Liver Fibrosis

Diagnostic Accuracy of Transient Elastography for Staging Liver Fibrosis in Autoimmune Liver Diseases: A Systematic Review and Meta-Analysis

Metabolomic Profiling of Autoimmune Hepatitis: the Diagnostic Utility of Nuclear Magnetic Resonance Spectroscopy

A meta-analysis on the diagnostic performance of magnetic resonance imaging and transient elastography in nonalcoholic fatty liver disease

Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease

Assessment of Liver Fibrosis Using Pharmacokinetic Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

NMR-based metabolomic signature: An important tool for the diagnosis and to study pathogenesis of autoimmune hepatitis

Noninvasive diagnosis of liver cirrhosis: qualitative and quantitative imaging biomarkers

Autoimmune Hepatitis: A Diagnostic and Therapeutic Overview

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease

Diagnostic Role of Transient Elastography in Patients with Autoimmune Liver Diseases: A Systematic Review and Meta-Analysis

Autoimmune Hepatitis: A Review of Current Diagnosis and Treatment

Hepatic expression of tumor necrosis factor-α and evaluation of MAPK-p38 and NFκB signaling pathways in autoimmune hepatitis